Icodec insulin - revolution in diabetes type 2 insulin therapy

Dobrzyński Michał, Czarnota Jakub, Skubel Tomasz, Drozd Małgorzata, Dudek Iga, Rybak Natalia. Icodec insulin - revolution in diabetes type 2 insulin therapy. Journal of Education, Health and Sport. 2022;12(8):1136-1142. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2022.12.08.097 https://apcz.umk.pl/JEHS/article/view/JEHS.2022.12.08.097 https://zenodo.org/record/7021619 The journal has had 40 points in Ministry of Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of December 21, 2021. No. 32343. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical Culture Sciences (Field of Medical sciences and health sciences); Health Sciences (Field of Medical Sciences and Health Sciences). Punkty Ministerialne z 2019 - aktualny rok 40 punktów. Załącznik do komunikatu Ministra Edukacji i Nauki z dnia 21 grudnia 2021 r. Lp. 32343. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu). © The Authors 2022; This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 02.08.2022. Revised: 07.08.2022. Accepted: 25.08.2022. Icodec insulin - revolution in diabetes type 2 insulin therapy Michał Dobrzyński https://orcid.org/0000-0002-1416-6568 mdobrzyski4@gmail.com 1 Military Clinical Hospital with a Polyclinic in Lublin, Al. Racławickie 23, 20-904 Lublin Jakub Czarnota https://orcid.org/0000-0003-2783-0349 lek.jakub.czarnota@interia.pl Specialist Hospital In Radom of the name Tytus Chałubiński, Adolfa Tochtermana 1, 26-610 Radom Tomasz Skubel https://orcid.org/0000-0001-7572-401X tomasz.wojciech.skubel@gmail.com 1 Military Clinical Hospital with a Polyclinic in Lublin, Al. Racławickie 23, 20-904 Lublin Małgorzata Drozd https://orcid.org/0000-0002-0710-2451 drozd.malg@gmail.com Independent Public Clinical Hospital No. 4 in Lublin, Jaczewskiego 8, 20-954 Lublin Iga Dudek https://orcid.org/0000-0002-8101-074X; iga.dudek6@gmail.com 1 Military Clinical Hospital with a Polyclinic in Lublin, Al. Racławickie 23, 20-904 Lublin Natalia Rybak https://orcid.org/0000-0003-1437-7661 natalia.rybcia@gmail.com Independent Public Clinical Hospital No. 4 in Lublin, Jaczewskiego 8, 20-954 Lublin Abstract Introduction: Basal glucose control in diabetes type 2 is commonly maintained by a single, once-daily administration of insulin through subcutaneous injection. Insulin icodec, a novel ultralong-acting lipidated analog validates the concept of a once-weekly basal injection that is less burdensome, yet equally safe and efficacious as conventional once-daily treatment. Aim: The aim of the study is to introduce once-weekly injected insulin therapy and compare it with conventional basal insulin therapy in diabetes type 2 patients. Results: The results from phase II trials suggest that switching from an existing basal insulin to icodec, with or without a loading dose, provides effective glycemic control with comparable risk of hypoglycemia.In one of the studies TIR improved from baseline (mean: A 57.0%; B 55.2%; C 51.0%; IGlar U100 55.3%) through weeks 15 and 16 (estimated mean: A 76.6%; B 83.0%; C 80.9%; IGlar U100, 75.9%). No unexpected side effects were observed. It was reassuring that not a single episode of severe hypoglycemia (level 3) was reported for any treatment group throughout the trial duration and that the time spent below range (<3.9 mmol/L [